Drug Companies Update Nov 2007
Mergers, acquisitions & Joint Ventures
- Adnexus, a company investigating targeted biologics, has been acquired by Bristol-Myers Squibb..
- Advanced Cell Techonolgy has acquired Mytogen, a biotech company developing cell-therapy products.
- Allergan has acquired Esprit Pharma which is now a wholly-owned subsidiary.
- Macroflux has changed its name and will henceforth be known as Zosano Pharma.
- PacMab ltd has changed its name to Immune System Therapeutics ltd.
- Schering-Plough has acquired Organon (and Nobilon) which were subsidiaries of Akzo Nobel. This essentially ends Akzo Nobel's involvement in pharma.
- Swedish company Meda has acquired Medpointe.
New Companies
- Aquinox Pharmaceuticals is interested in the development and commercialisation of novel and targeted small molecules for the treatment of cancer and inflammatory disease.
- AlloCure is focused on the development of stem cell therapies for the treatment of various indications.
- Bennu Pharmaceuticals is a wholly-owned subsidiary of Raptor Pharmaceuticals and is responsible for the development of internally-discovered therapeutic candidates based on Raptor's novel drug delivery platforms.
- Biocontrol Ltd. develops safe, specific, effective and adaptable biological agents for use in unmet disease areas.
- BioMarck Pharmaceuticals is investigating drugs for pulmonary and hypersecretory diseases.
- Cavit Sciences is a biotechnology company engaged in developing treatments for cancer and viral infections.
- Cinkate is a hybrid Chinese/International pharmaceutical company, focussing on the development of products for immunological diseases.
- Cogentus Pharmaceuticals develops next-generation fixed-dose combination formulations of established drugs.
- Deciphera Pharmaceuticals is developing small molecules switch inhibitors of protein kinases using its proprietary Phylomechanics technology.
- DermiPsor (non-english site link) is an Israeli company developing a novel formulation of calcipotriol and nicotinamide for the treatment of psoriasis.
- Diabetology is employing a proprietary oral delivery system to administer known bioactives and novel compounds for the treatment of diabetes.
- German-company JADO Technologies develops treatments for a wide range of diseases using its proprietary RAFT Intervention Technology.
- Kenta Biotech is developing fully-human MAbs to treat serious infectious diseases.
- Metatstatix is an emerging pharmaceutical company focusing on small-molecule chemokine receptor inhibitors for the treatment of severely debilitating diseases.
- Meyer Pharmaceuticals is a biotechnology company focused on the development of biological products for the treatment of inflammatory and immunological disorders.
- Privately-owned Neurotune develops small molecules for the treatment of disorders in the peripheral and central nervous system, and age-related atrophy.
- Patrys is engaged in the development of novel therapeutic approaches to cancer and other diseases.
- Tolera Therapeutics is engaged in the development of novel therapies and technologies related to immune suppression and modulation.
